Show simple item record

dc.contributor.authorDurán, Verónica
dc.contributor.authorGrabski, Elena
dc.contributor.authorHozsa, Constantin
dc.contributor.authorBecker, Jennifer
dc.contributor.authorYasar, Hanzey
dc.contributor.authorMonteiro, João T
dc.contributor.authorCosta, Bibiana
dc.contributor.authorKoller, Nicole
dc.contributor.authorLueder, Yvonne
dc.contributor.authorWiegmann, Bettina
dc.contributor.authorBrandes, Gudrun
dc.contributor.authorKaever, Volkhard
dc.contributor.authorLehr, Claus-Michael
dc.contributor.authorLepenies, Bernd
dc.contributor.authorTampé, Robert
dc.contributor.authorFörster, Reinhold
dc.contributor.authorBošnjak, Berislav
dc.contributor.authorFurch, Marcus
dc.contributor.authorGraalmann, Theresa
dc.contributor.authorKalinke, Ulrich
dc.date.accessioned2021-06-14T12:25:37Z
dc.date.available2021-06-14T12:25:37Z
dc.date.issued2021-04-16
dc.identifier.citationJ Control Release. 2021 Jun 10;334:201-212. doi: 10.1016/j.jconrel.2021.04.012. Epub 2021 Apr 16.en_US
dc.identifier.pmid33865899
dc.identifier.doi10.1016/j.jconrel.2021.04.012
dc.identifier.urihttp://hdl.handle.net/10033/622904
dc.description.abstractAntibiotic treatment of tuberculosis (TB) is complex, lengthy, and can be associated with various adverse effects. As a result, patient compliance often is poor, thus further enhancing the risk of selecting multi-drug resistant bacteria. Macrophage mannose receptor (MMR)-positive alveolar macrophages (AM) constitute a niche in which Mycobacterium tuberculosis replicates and survives. Therefore, we encapsulated levofloxacin in lipid nanocarriers functionalized with fucosyl residues that interact with the MMR. Indeed, such nanocarriers preferentially targeted MMR-positive myeloid cells, and in particular, AM. Intracellularly, fucosylated lipid nanocarriers favorably delivered their payload into endosomal compartments, where mycobacteria reside. In an in vitro setting using infected human primary macrophages as well as dendritic cells, the encapsulated antibiotic cleared the pathogen more efficiently than free levofloxacin. In conclusion, our results point towards carbohydrate-functionalized nanocarriers as a promising tool for improving TB treatment by targeted delivery of antibiotics.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAlveolar macrophagesen_US
dc.subjectLiposomesen_US
dc.subjectNanomedicineen_US
dc.subjectTargeted drug deliveryen_US
dc.subjectTuberculosisen_US
dc.titleFucosylated lipid nanocarriers loaded with antibiotics efficiently inhibit mycobacterial propagation in human myeloid cells.en_US
dc.typeArticleen_US
dc.identifier.eissn1873-4995
dc.contributor.departmentTWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.;HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalJournal of controlled release : official journal of the Controlled Release Societyen_US
dc.source.volume334
dc.source.beginpage201
dc.source.endpage212
refterms.dateFOA2021-06-14T12:25:38Z
dc.source.journaltitleJournal of controlled release : official journal of the Controlled Release Society
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Duran et al.pdf
Size:
10.16Mb
Format:
PDF
Description:
Open Access article
Thumbnail
Name:
Duran et al.pdf
Size:
10.16Mb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International